Loading…

Public–private partnerships in translational medicine: Concepts and practical examples

The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships h...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2012-07, Vol.161 (2), p.416-421
Main Authors: Luijten, Peter R., van Dongen, Guus A.M.S., Moonen, Chrit T., Storm, Gert, Crommelin, Daan J.A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3
cites cdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3
container_end_page 421
container_issue 2
container_start_page 416
container_title Journal of controlled release
container_volume 161
creator Luijten, Peter R.
van Dongen, Guus A.M.S.
Moonen, Chrit T.
Storm, Gert
Crommelin, Daan J.A.
description The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument. Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery. [Display omitted]
doi_str_mv 10.1016/j.jconrel.2012.03.012
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1021127849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365912001988</els_id><sourcerecordid>1021127849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</originalsourceid><addsrcrecordid>eNqFkM9O3DAQh62qqCyUR2ibYy8JYzuOnV4qtCp_JCSQKBI3y3EmrVdZJ7W9CG68A2_YJ6nRLlyrOfwO883Y8xHyiUJFgTbHq2plJx9wrBhQVgGvcrwjC6okL-u2Fe_JInOq5I1o98lBjCsAELyWH8g-Y3UjeAsLcne96UZn_z49z8Hdm4TFbELyGOJvN8fC-SIF4-Nokpu8GYs19s46j9-K5eQtzikWxvfFHIxNzmYAH8x6HjF-JHuDGSMe7fKQ3J7--Lk8Ly-vzi6WJ5el5apNZS2NAcVU14OQSgrJeuQgW85lLerGggFOWWfVMKi-hn6wudEJqppOSt52_JB83e6dw_RngzHptYsWx9F4nDZRU2CUMqnqNqNii9owxRhw0PnmtQmPGdIvUvVK76TqF6kauM6R5z7vnth0-f63qVeLGfiyBQYzafMruKhvb_IGAUBlkysT37cEZhX3DoOO1mEW2LuANul-cv_5xD-64ZVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1021127849</pqid></control><display><type>article</type><title>Public–private partnerships in translational medicine: Concepts and practical examples</title><source>ScienceDirect Freedom Collection</source><creator>Luijten, Peter R. ; van Dongen, Guus A.M.S. ; Moonen, Chrit T. ; Storm, Gert ; Crommelin, Daan J.A.</creator><creatorcontrib>Luijten, Peter R. ; van Dongen, Guus A.M.S. ; Moonen, Chrit T. ; Storm, Gert ; Crommelin, Daan J.A.</creatorcontrib><description>The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument. Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery. [Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2012.03.012</identifier><identifier>PMID: 22465390</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; climate ; diagnostic techniques ; Drug Industry ; drugs ; HIFU ; Humans ; Image guided drug delivery ; Magnetic Resonance Imaging ; medicine ; Molecular Imaging ; MRI ; Netherlands ; new products ; PET ; Positron-Emission Tomography ; Public-Private Sector Partnerships ; Public–private partnerships ; technology ; translation (genetics) ; Translational Medical Research ; ultrasonics ; Universities</subject><ispartof>Journal of controlled release, 2012-07, Vol.161 (2), p.416-421</ispartof><rights>2012 Elsevier B.V.</rights><rights>Copyright © 2012 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</citedby><cites>FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22465390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luijten, Peter R.</creatorcontrib><creatorcontrib>van Dongen, Guus A.M.S.</creatorcontrib><creatorcontrib>Moonen, Chrit T.</creatorcontrib><creatorcontrib>Storm, Gert</creatorcontrib><creatorcontrib>Crommelin, Daan J.A.</creatorcontrib><title>Public–private partnerships in translational medicine: Concepts and practical examples</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument. Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery. [Display omitted]</description><subject>Animals</subject><subject>climate</subject><subject>diagnostic techniques</subject><subject>Drug Industry</subject><subject>drugs</subject><subject>HIFU</subject><subject>Humans</subject><subject>Image guided drug delivery</subject><subject>Magnetic Resonance Imaging</subject><subject>medicine</subject><subject>Molecular Imaging</subject><subject>MRI</subject><subject>Netherlands</subject><subject>new products</subject><subject>PET</subject><subject>Positron-Emission Tomography</subject><subject>Public-Private Sector Partnerships</subject><subject>Public–private partnerships</subject><subject>technology</subject><subject>translation (genetics)</subject><subject>Translational Medical Research</subject><subject>ultrasonics</subject><subject>Universities</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkM9O3DAQh62qqCyUR2ibYy8JYzuOnV4qtCp_JCSQKBI3y3EmrVdZJ7W9CG68A2_YJ6nRLlyrOfwO883Y8xHyiUJFgTbHq2plJx9wrBhQVgGvcrwjC6okL-u2Fe_JInOq5I1o98lBjCsAELyWH8g-Y3UjeAsLcne96UZn_z49z8Hdm4TFbELyGOJvN8fC-SIF4-Nokpu8GYs19s46j9-K5eQtzikWxvfFHIxNzmYAH8x6HjF-JHuDGSMe7fKQ3J7--Lk8Ly-vzi6WJ5el5apNZS2NAcVU14OQSgrJeuQgW85lLerGggFOWWfVMKi-hn6wudEJqppOSt52_JB83e6dw_RngzHptYsWx9F4nDZRU2CUMqnqNqNii9owxRhw0PnmtQmPGdIvUvVK76TqF6kauM6R5z7vnth0-f63qVeLGfiyBQYzafMruKhvb_IGAUBlkysT37cEZhX3DoOO1mEW2LuANul-cv_5xD-64ZVs</recordid><startdate>20120720</startdate><enddate>20120720</enddate><creator>Luijten, Peter R.</creator><creator>van Dongen, Guus A.M.S.</creator><creator>Moonen, Chrit T.</creator><creator>Storm, Gert</creator><creator>Crommelin, Daan J.A.</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120720</creationdate><title>Public–private partnerships in translational medicine: Concepts and practical examples</title><author>Luijten, Peter R. ; van Dongen, Guus A.M.S. ; Moonen, Chrit T. ; Storm, Gert ; Crommelin, Daan J.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>climate</topic><topic>diagnostic techniques</topic><topic>Drug Industry</topic><topic>drugs</topic><topic>HIFU</topic><topic>Humans</topic><topic>Image guided drug delivery</topic><topic>Magnetic Resonance Imaging</topic><topic>medicine</topic><topic>Molecular Imaging</topic><topic>MRI</topic><topic>Netherlands</topic><topic>new products</topic><topic>PET</topic><topic>Positron-Emission Tomography</topic><topic>Public-Private Sector Partnerships</topic><topic>Public–private partnerships</topic><topic>technology</topic><topic>translation (genetics)</topic><topic>Translational Medical Research</topic><topic>ultrasonics</topic><topic>Universities</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luijten, Peter R.</creatorcontrib><creatorcontrib>van Dongen, Guus A.M.S.</creatorcontrib><creatorcontrib>Moonen, Chrit T.</creatorcontrib><creatorcontrib>Storm, Gert</creatorcontrib><creatorcontrib>Crommelin, Daan J.A.</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luijten, Peter R.</au><au>van Dongen, Guus A.M.S.</au><au>Moonen, Chrit T.</au><au>Storm, Gert</au><au>Crommelin, Daan J.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Public–private partnerships in translational medicine: Concepts and practical examples</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2012-07-20</date><risdate>2012</risdate><volume>161</volume><issue>2</issue><spage>416</spage><epage>421</epage><pages>416-421</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>The way forward in multidisciplinary research according to former NIH's director Elias Zerhouni is to engage in predictive, personalized, preemptive and participatory medicine. For the creation of the optimal innovation climate that would allow for such a strategy, public–private partnerships have been widely proposed as an important instrument. Public–private partnerships have become an important instrument to expedite translational research in medicine. The Netherlands have initiated three large public–private partnerships in the life sciences and health area to facilitate the translation of valuable basic scientific concepts to new products and services in medicine. The focus of these partnerships has been on drug development, improved diagnosis and regenerative medicine. The Dutch model of public–private partnership forms the blueprint of a much larger European initiative called EATRIS [1]. This paper will provide practical examples of public–private partnerships initiated to expedite the translation of new technology for drug development towards the clinic. Three specific technologies are in focus: companion diagnostics using nuclear medicine, the use of ultra high field MRI to generate sensitive surrogate endpoints based on endogenous contrast, and MRI guidance for High Intensity Focused Ultrasound mediated drug delivery. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>22465390</pmid><doi>10.1016/j.jconrel.2012.03.012</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2012-07, Vol.161 (2), p.416-421
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_1021127849
source ScienceDirect Freedom Collection
subjects Animals
climate
diagnostic techniques
Drug Industry
drugs
HIFU
Humans
Image guided drug delivery
Magnetic Resonance Imaging
medicine
Molecular Imaging
MRI
Netherlands
new products
PET
Positron-Emission Tomography
Public-Private Sector Partnerships
Public–private partnerships
technology
translation (genetics)
Translational Medical Research
ultrasonics
Universities
title Public–private partnerships in translational medicine: Concepts and practical examples
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A44%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Public%E2%80%93private%20partnerships%20in%20translational%20medicine:%20Concepts%20and%20practical%20examples&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Luijten,%20Peter%20R.&rft.date=2012-07-20&rft.volume=161&rft.issue=2&rft.spage=416&rft.epage=421&rft.pages=416-421&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2012.03.012&rft_dat=%3Cproquest_cross%3E1021127849%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-47aa0828bd05787572de30793374546c0a0312bc8ff8d40dfc374b5186b7739b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1021127849&rft_id=info:pmid/22465390&rfr_iscdi=true